MedWatch

Novo Seeds looking to expand its investment team

In just one year Novo Seeds has lost two of its investment executives to foreign venture capitalist firms, and the company has brought one in from abroad. As Novo Seeds’ investment framework steadily grows, the group will need to bring in additional experienced people.

Investment executives at Novo Seeds are currently working extra fast in order to get everything done, and Søren Møller, managing partner at Novo A/S’ organization for early-phase investments, readily acknowledges this fact.

The reason is quite simple, namely that Novo Seeds has lost two experienced investment executives in the period from August 2014 to August 2015. First to leave was Henrijette Richter, who last year switched to the prominent French venture firm Sofinnova Partners, and most recently  Bobby Soni, who left for similarly renowned, UK-based Imperial Innovations.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

CHMP blåstempler ni nye lægemidler i maj

Den europæiske lægemiddelkomite, CHMP, har på dets møde i maj indstillet ni nye lægemidler til godkendelse samt anbefalet, at seks midler kan tages i brug på nye måder. To midler afvist.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier